Joke Temmerman

Dr. Joke Temmerman

Universiteit Antwerpen, Department of Biomedical Sciences and Institute Born-Bunge
+2
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2021 in Molecular Autism
Verified
Journal Article
Open access
PDF file
LSLaurie-Anne Sapey-Triomphe
Laurie-Anne Sapey-Triomphe
Joke TemmermanJoke Temmerman
Joke Temmerman
NPNicolaas A. J. Puts
Nicolaas A. J. Puts
JWJohan Wagemans
Johan Wagemans
Background: According to Bayesian hypotheses, individuals with Autism Spectrum Disorder (ASD) have difficulties making accurate predictions about their environment. In particular, the mechanisms by which they assign precision to predictions or sensory inputs would be suboptimal in ASD. These mechanisms are thought to be mostly mediated by glutamate and GABA. Here, we aimed to shed light on prediction learning in ASD and on its neurobiological correlates. Methods: Twenty-six neurotypical and 26 autistic adults participated in an associative learning task where they had to learn a probabilistic association between a tone and the rotation direction of two dots, in a volatile context. They also took part in magnetic resonance spectroscopy (MRS) measurements to quantify Glx (glutamate and glutamine), GABA + and glutathione in a low-level perceptual region (occipital cortex) and in a higher-level region involved in prediction learning (inferior frontal gyrus). Results: Neurotypical and autistic adults had their percepts biased by their expectations, and this bias was smaller for individuals with a more atypical sensory sensitivity. Both groups were able to learn the association and to update their beliefs after a change in contingency. Interestingly, the percentage of correct predictions was correlated with the Glx/GABA + ratio in the occipital cortex (positive correlation) and in the right inferior frontal gyrus (negative correlation). In this region, MRS results also showed an increased concentration of Glx in the ASD group compared to the neurotypical group. Limitations: We used a quite restrictive approach to select the MR spectra showing a good fit, which led to the exclusion of some MRS datasets and therefore to the reduction of the sample size for certain metabolites/regions. Conclusions: Autistic adults appeared to have intact abilities to make predictions in this task, in contrast with the Bayesian hypotheses of ASD. Yet, higher ratios of Glx/GABA + in a frontal region were associated with decreased predictive abilities, and ASD individuals tended to have more Glx in this region. This neurobiological difference might contribute to suboptimal predictive mechanisms in ASD in certain contexts.

20 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Joke TemmermanJoke Temmerman
Joke Temmerman
FVFloris Van Der Veken
Floris Van Der Veken
SESebastiaan Engelborghs
Sebastiaan Engelborghs
KGKaat Guldolf
Kaat Guldolf
GNGuy Nagels
Guy Nagels
MDMiguel D’haeseleer
Miguel D’haeseleer
Multiple sclerosis (MS) is a chronic inflammatory demyelinating and degenerative disorder of the central nervous system. Accelerated brain volume loss (BVL) has emerged as a promising magnetic resonance imaging marker (MRI) of neurodegeneration, correlating with present and future clinical disability. We have systematically selected MS patients fulfilling ‘no evidence of disease activity-3′ (NEDA-3) criteria under high-efficacy disease-modifying treatment (DMT) from the database of two Belgian MS centers. BVL between both MRI scans demarcating the NEDA-3 period was assessed and compared with a group of prospectively recruited healthy volunteers who were matched for age and gender. Annualized whole brain volume percentage change was similar between 29 MS patients achieving NEDA-3 and 24 healthy controls (−0.25 ± 0.49 versus −0.24 ± 0.20, p = 0.9992; median follow-up 21 versus 33 months; respectively). In contrast, we found a mean BVL increase of 72%, as compared with the former, in a second control group of MS patients (n = 21) whom had been excluded from the NEDA-3 group due to disease activity (p = 0.1371). Our results suggest that neurodegeneration in MS can slow down to the rate of normal aging once inflammatory disease activity has been extinguished and advocate for an early introduction of high-efficacy DMT to reduce the risk of future clinical disability.

4 September 2025
Verified
Thesis
Closed access
Joke TemmermanJoke Temmerman
Joke Temmerman
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, and degenerative disease of the central nervous system and the leading cause of non-traumatic neurological disability in young to middle-aged adults. Despite the efficacy of disease-modifying treatments (DMTs) in reducing relapses and lesion accumulation, many patients experience disability progression independent of relapses. This underscores the need for reliable biomarkers that capture subtle disease processes to improve monitoring and support individualized treatment. The aim of this thesis was to investigate neuroinflammatory and neurodegenerative biomarkers associated with MS worsening, using clinically representative, real-world cohorts. Both fluid- and imaging-based biomarkers were evaluated for their prognostic potential and applicability in clinical practice. Our results showed that brain volume loss (BVL), measured via MRI, was comparable between patients meeting the “no evidence of disease activity-3” criteria under high-efficacy DMT and healthy controls, whereas patients with evidence of disease activity exhibited a 72% higher BVL rate. This suggests that timely initiation of effective therapy may reduce neurodegeneration to levels seen in physiological aging. In another longitudinal MRI study, gray matter (GM) atrophy rate was significantly associated with worsening manual dexterity and composite disability scores, despite no overall difference in BVL between MS patients and controls. These findings underscore the clinical relevance of GM-specific measures while also highlighting technical challenges that currently limit the implementation of BVL metrics in routine care. Finally, serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NF-L) were jointly evaluated in a clinically representative cohort. Patients with elevated serum levels of both markers showed greater BVL than those with NF-L elevation alone, indicating that GFAP provides complementary information on neurodegeneration. GFAP was associated with both global and regional brain atrophy, whereas NF-L was more specifically related to GM volumes, suggesting distinct spatial patterns of pathology. In conclusion, our research supports a multimodal biomarker framework that integrates imaging and fluid measures to more comprehensively monitor the overlapping but distinct processes of inflammation and neurodegeneration in MS. Addressing current methodological and technical barriers will be essential for implementing these findings into routine clinical practice.